CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., a privately-held oncology drug development company, today announced the completion of enrollment of its Phase 2 study of Xanafide® (amonafide malate) for the treatment of patients with secondary acute myeloid leukemia (AML).
